Arcutis Biotherapeutics is back in focus as price targets cluster around $35, with at least one firm trimming its view from $37 to $35 while others move targets from the low $30s to the mid $30s.
The new guidelines, published in the Journal of the American Academy of Dermatology (JAAD), will guide dermatologists in deciding the best possible prevention and treatment options for pediatric ...
Everyday Health on MSN
Can taking a GLP-1 drug every other week help you keep the weight off?
Preliminary research suggests that people who’ve used GLP-1 drugs to reach a healthy weight can spread out their injections without regaining lost pounds.
A budget proposal released last week by the Trump administration seeks to cut $5 billion from the National Institutes of ...
The Food and Drug Administration has recalled nearly 90,000 bottles of Taro Pharmaceuticals’ Children’s Ibuprofen Oral ...
Platform leverages muscle biology to de-risk development and identify new therapeutic targets ahead of clinical entry ...
On 30 March, 2026, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) announced that the ...
This high dose nusinersen regimen for spinal muscular atrophy includes 50mg loading doses and 28mg maintenance doses.
MDA’s research funding for Dr. Adrian Krainer’s research led to the groundbreaking discovery of SPINRAZA®. FDA Approves High ...
Ad hoc announcement pursuant to Art. 53 LR Phase 2 results show a statistically significant dose-dependent response on total sleep time with clinically meaningful improvements across multiple sleep ...
Global assessment and itch/scratch scores highlight the effectiveness of topical roflumilast for treating atopic dermatitis in children 3 months to 2 years old, in a phase 2 study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results